Source document: https://docs-lawep.s3.us-east-2.amazonaws.com/1698847026790.pdf (New Zealand)
2015/180 Medicines Amendment Regulations (No 2) 2015 Jerry Mateparae, Governor-General Order in Council At Wellington this 27th day of July 2015 Present: His Excellency the Governor-General in Council Pursuant to section 105(1)(j) of the Medicines Act 1981, His Excellency the Govern- or-General makes the following regulations, acting— on the advice and with the consent of the Executive Council; and on the advice of the Minister of Health tendered after consultation with the or- ganisations or bodies appearing to the Minister to be representative of persons likely to be substantially affected.
Contents Page (a) (b) 1 2 3 4 Title Commencement Principal regulations Schedule 1 replaced Schedule Schedule 1 replaced Regulations 1 Title These regulations are the Medicines Amendment Regulations (No 2) 2015.

1 2 2 2 2 1 r 2 2 3 4 Medicines Amendment Regulations (No 2) 2015 2015/180 Commencement These regulations come into force on 6 August 2015.

Principal regulations These regulations amend the Medicines Regulations 1984 (the principal regu- lations).
Schedule 1 replaced Replace Schedule 1 with the Schedule 1 set out in the Schedule of these regula- tions.

Schedule Schedule 1 replaced Schedule 1 Prescription, restricted, and pharmacy-only medicines r 4 r 3 Every reference to a medicine in this schedule applies whether the medicine is syn- thetic in origin or is from biological or mineral sources.
Unless specific reference is made otherwise, every reference applies also to medicines that are— • • • • preparations and admixtures containing any proportion of any substance listed in this schedule: salts and esters of any substance listed in this schedule: preparations or extracts of biological materials listed in this schedule: salts or oxides of elements listed in this schedule.
Unless specific reference is made otherwise, every reference to a medicine in this schedule applies,— • • if the medicine is an injection or eye preparation, to any concentration of that medicine; and if the medicine is not an injection or eye preparation, only if the concentration of the medicine is greater than 10 milligrams per litre or per kilogram.
Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol, or element unless specifically stated otherwise.

2 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule Part 1 Prescription medicines Amending or replacing this Part may affect designated prescriber regulations under section 105(1)(q) of the Act.
19-norandrostenedione 2,4-dinitrochlorobenzene 4-aminopyridine 4-chloromethandienone 4-chlorotestosterone 5-aminolevulinic acid Abacavir Abatacept Abciximab Abiraterone Abrus precatorius; at all strengths Acamprosate Acarbose Acebutolol Acepromazine Acetanilides Acetarsol Acetazolamide Acetohexamide Acetylcarbromal Acetylcholine; except in medicines containing 1 milligram or less per litre or per kilogram Acetylcysteine; for injection or inhalation Acetyldigitoxin Acetylmethyldimethyloximidophenylhydrazine Acetylstrophanthidin Aciclovir; except for external use for the treatment of herpes labialis Acipimox Acitretin Aclidinium bromide Acokanthera ouabaio 3 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 Acokanthera schimperi Aconitum spp; except when specified elsewhere in this schedule Acrivastine Adalimumab Adapalene Adefovir Adenosine; for injection Adinazolam Adiphenine Adonis vernalis Adrafinil Adrenal extract; except for dermal use in medicines containing 0.02% or less of ketosteroids Adrenaline; in medicines containing more than 1% Adrenocortical hormones; except adrenal extract for dermal use containing 0.02% or less of ketosteroids Afamelanotide Afatinib Aflibercept Agalsidase Agomelatine Alatrofloxacin Albendazole Albumin; except human albumin Alclofenac Alclometasone; except when specified elsewhere in this schedule Alcohol; for injection in medicines containing more than 20% Alcuronium Aldesleukin
 Aldosterone; except in medicines containing 10 micrograms or less per litre or per kilogram Alefacept Alemtuzumab Alendronic acid Alfacalcidol 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule Alfentanil Alfuzosin Alglucerase Alglucosidase Aliskiren Alkyl sulfonals Allergens Allopurinol
 Allylisopropylacetylurea; at all strengths Allyloestrenol Alogliptin Alosetron Alpha1-proteinase inhibitor Alphadolone Alphaxalone Alprazolam Alprenolol Alprostadil Alseroxylon Alteplase Altretamine Amantadine Ambenonium Ambrisentan Ambucetamide Ambutonium Amcinonide Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board Amfebutamone Amfepramone Amidopyrine Amifostine Amikacin 5 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 96 97 98 99 Amiloride Aminocaproic acid Aminoglutethimide Aminometradine 100 Aminophenazone; at all strengths 101 Aminophylline; except for oral use in liquid form in medicines containing 2% or less 102 Aminopterin 103 Aminorex 104 Aminosalicylic acid 105 Amiodarone 106 Amiphenazole 107 Amisometradine 108 Amisulpride 109 Amitriptyline 110 Amlodipine 111 Ammi visnaga 112 Ammonium bromide 113 Amobarbital 114 Amodiaquine 115 Amorolfine; except when specified elsewhere in this schedule; except in prep- arations for the treatment of tinea pedis only or when sold in practice by a po- diatrist registered with the Podiatrists Board 116 Amoxapine 117 Amoxycillin 118 Amphomycin 119 Amphotericin 120 Ampicillin 121 Amprenavir 122 Amrinone 123 Amsacrine 124 Amygdalin; at all strengths 125 Amyl nitrite; except when sold to a person who holds a controlled substances licence (issued
 under section 95B of the Hazardous Substances and New Or- ganisms Act 1996) authorising the person to possess cyanide; except when sold 6 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule to an exempt laboratory covered by a Hazardous Substances and New Organ- isms Act 1996 approved code of practice 126 Amylocaine 127 Anabolic steroids 128 Anagrelide 129 Anakinra 130 Anastrozole 131 Ancestim 132 Anchusa officinalis; at all strengths 133 Ancrod and its immunoglobulin antidote 134 Androgenic and
 anabolic steroidal agents 135 Androgens 136 Androisoxazole 137 Androstanolone 138 Androstenediol 139 Androstenedione 140 Anecortave 141 Angiotensinamide 142 Anidulafungin 143 Anistreplase 144 Antazoline; except for ophthalmic use 145 Antibiotic substances; except when specified elsewhere in this schedule 146 Antigens 147 Antihistamines; except when specified elsewhere in this schedule 148 Antimony; except in medicines containing 1 milligram or less per litre or per kilogram 149 Antisera; for injection 150 Apixaban 151 Apocynum spp 152 Apomorphine; except in medicines containing 1 milligram or less per litre or per kilogram 153 Apraclonidine 154 Aprepitant 155 Apronal 156 Aprotinin 7 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 157 Arecoline 158 Aripiprazole 159 Aristolochia spp; at all strengths 160 Aristolochic acid; at all strengths 161 Arsenic; except in medicines containing 1 milligram or less per litre or per kilogram 162 Artemether 163 Articaine; except when used as a local anaesthetic in practice by a dental thera- pist registered with the Dental Council 164 Asenapine 165 Asparaginase 166 Aspirin; for injection; when combined with caffeine, paracetamol, or salicyla- mide 167 Astemizole 168 Atamestane 169 Atazanavir 170 Atenolol 171 Atomoxetine 172 Atorvastatin 173 Atosiban 174 Atovaquone 175 Atracurium 176 Atropa belladonna; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less of total
 solanaceous alkaloids per litre or per kilogram 177 Atropine; except when specified elsewhere in this schedule; except when used as an antidote in a device designed for self-injection; except in medicines con- taining 300 micrograms or less per litre or per kilogram 178 Atropine methonitrate 179 Auranofin 180 Aurothiomalate sodium 181 Avanafil 182 Aviptadil 183 Axitinib 184 Azacitidine 185 Azacyclonol 8 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 186 Azapropazone 187 Azaribine 188 Azatadine;
 except when specified elsewhere in this schedule 189 Azathioprine 190 Azelaic acid; except for dermal use 191 Azelastine; except when specified elsewhere in this schedule 192 Azithromycin 193 Azlocillin 194 Aztreonam 195 Bacampicillin 196 Bacitracin 197 Baclofen 198 Balsalazide 199 Bambuterol 200 Bamethan 201 Bamipine 202 Barbital 203 Barbiturates 204 Basiliximab 205 Bazedoxifene 206 Becaplermin 207 Beclamide 208 Beclomethasone; except when specified elsewhere in this schedule 209 Belatacept 210 Belimumab 211 Bemegride 212 Benactyzine 213 Benazepril 214 Bendamustine 215 Bendrofluazide 216 Benethamine penicillin 217 Benorylate 218 Benoxaprofen 219 Benperidol 220 Benserazide 9 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 221 Benzathine penicillin 222 Benzatropine 223 Benzhexol 224 Benzilonium 225 Benzocaine; except when specified elsewhere in this schedule; except in der- mal preparations containing 2% or less of total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit 226 Benzodiazepines 227 Benzoyl metronidazole 228 Benzoyl peroxide; except for external use in medicines containing 10% or less 229 Benzthiazide 230 Benzydamine; for internal use 231 Benzylpenicillin 232 Bepridil 233 Beractant 234 Besifloxacin 235 Beta carotene; in medicines containing more than 18 milligrams per recom- mended daily dose 236 Betahistine 237 Betamethasone 238 Betaxolol 239 Bethanechol 240
 Bethanidine 241 Bevacizumab 242 Bevantolol 243 Bexarotene 244 Bezafibrate 245 Bicalutamide 246 Bifonazole; except for dermal use 247 Bimatoprost 248 Biperiden 249 Bismuth; except for external use in medicines containing 3% or less 250 Bisoprolol 251 Bithionol; at all strengths 10 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 252 Bivalirudin 253 Bleomycin 254 Boceprevir 255 Bolandiol 256 Bolasterone 257 Bolazine 258 Boldenone 259 Bolenol 260 Bolmantalate 261 Boron, including borax and boric acid;
 except for internal use in medicines containing 6 milligrams or less per recommended daily dose; except in dermal medicines for use other than paediatric use containing 0.35% or less; except when present as an excipient 262 Bortezomib 263 Bosentan 264 Botulinum toxins 265 Bretylium 266 Brimonidine 267 Brinzolamide 268 Bromazepam 269 Bromocriptine 270 Bromoform 271 Brompheniramine; except when specified elsewhere in this schedule 272 Bromvaletone 273 Brotizolam 274 Brugmansia spp 275 Buclizine; except for oral use 276 Budesonide; except when specified elsewhere in this schedule 277 Bufexamac; except in suppositories or for dermal use in medicines containing 5% or less 278 Bumetanide 279 Buniodyl sodium; at all strengths 280 Buphenine 281 Bupivacaine 282 Buprenorphine 11 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 283 Bupropion 284 Buserelin 285 Buspirone 286 Busulphan 287 Butacaine 288 Butobarbital 289 Butoconazole; except for vaginal use 290 Butorphanol 291 Butyl aminobenzoate; except for dermal use in medicines containing 2% or less 292 Butyl nitrite 293 Butylchloral hydrate 294 Cabazitaxel 295 Cabergoline 296 Cacalia spp; at all strengths 297 Cadmium 298 Calcipotriol; except in medicines containing not more than 50 micrograms per gram or per millilitre and when sold in a pack of not more than 30 grams or 30 millilitres by a pharmacist to an adult with mild to moderate psoriasis previous- ly diagnosed by a doctor 299 Calcitonin 300 Calcitriol 301
 Calcium carbimide 302 Calcium polystyrene sulphonate 303 Calotropis gigantea 304 Calotropis procera 305 Calusterone 306 Camazepam 307 Camphorated oil 308 Camphotamide 309 Canagliflozin 310 Canakinumab 311 Candesartan 312 Candicidin 313 Cannabidiol 12 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 314 Capecitabine 315 Capreomycin 316 Captodiame 317 Captopril 318 Capuride 319 Caramiphen 320 Carbachol 321 Carbamazepine 322 Carbaryl; except for external use in medicines containing 2% or less 323
 Carbazochrome 324 Carbenicillin 325 Carbenoxolone; for internal use 326 Carbetocin 327 Carbidopa 328 Carbimazole 329 Carbocromen 330 Carboplatin 331 Carboprost 332 Carbromal 333 Carbutamide 334 Carbuterol 335 Carindacillin 336 Carisoprodol 337 Carmustine 338 Carprofen 339 Carvedilol 340 Caspofungin 341 Catumaxomab 342 Cefacetrile 343 Cefaclor 344 Cefaloridine 345 Cefamandole 346 Cefapirin 347 Cefazolin 348 Cefepime 13 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 349 Cefetamet 350 Cefixime 351 Cefodizime 352 Cefonicid 353 Cefoperazone 354 Cefotaxime 355 Cefotetan 356 Cefotiam 357 Cefoxitin 358 Cefpirome 359 Cefpodoxime 360 Cefsulodin 361 Ceftaroline fosamil 362 Ceftazidime 363 Ceftibuten 364 Ceftolozane 365 Ceftriaxone 366 Cefuroxime 367 Celecoxib 368 Celiprolol 369 Cephaelis acuminata; except in medicines containing less than 0.2% of emetine 370 Cephaelis ipecacuanha; except in medicines containing less than 0.2% of emet- ine 371 Cephalexin 372 Cephalothin 373 Cephradine 374 Cerivastatin 375 Certolizumab pegol 376 Ceruletide 377 Cetirizine; except for oral use 378 Cetrorelix 379 Cetuximab 380 Chenodeoxycholic acid 381 Chloral hydrate; except for dermal use in medicines containing 2% or less 382 Chloralformamide 14 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 383 Chloralose 384 Chlorambucil 385 Chloramphenicol; except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when
 specified elsewhere in this schedule 386 Chlorandrostenolone 387 Chlorazanil 388 Chlorcyclizine 389 Chlordiazepoxide 390 Chlormerodrin 391 Chlormethiazole 392 Chlormezanone 393 Chloroform; for anaesthesia; except when specified elsewhere in this schedule 394 Chloroquine 395 Chlorothiazide 396 Chlorotrianisene 397 Chloroxydienone 398 Chloroxymesterone 399 Chlorpheniramine; except when specified elsewhere in this schedule 400 Chlorphentermine 401 Chlorpromazine 402 Chlorpropamide 403 Chlorprothixene 404
 Chlorquinaldol 405 Chlortetracycline 406 Chlorthalidone 407 Chlorzoxazone 408 Cholera vaccine; except in the form of an oral liquid containing vibrio cholerae when sold in a pharmacy by a registered pharmacist 409 Choline salicylate; except in medicines containing 10% or less and in pack sizes of 15 grams or less 410 Chorionic gonadotrophin; except in pregnancy test kits 411 Chymopapain 412 Ciclacillin 413 Ciclesonide 15 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 414 Ciclopirox; except for external use 415 Cidofovir 416 Cilastatin 417 Cilazapril 418 Cilostazol 419 Cimetidine; except when specified elsewhere in this schedule 420 Cinacalcet 421 Cinchocaine; for injection; for ophthalmic use; for external use in medicines containing more than 0.5% 422 Cinchophen 423 Cinoxacin 424 Ciprofloxacin 425 Cisapride 426 Cisatracurium 427 Cisplatin 428 Citalopram 429 Cladribine 430 Clarithromycin 431 Clavulanic acid 432 Clemastine; except for oral use 433 Clemizole 434 Clenbuterol 435 Clevidipine 436 Clidinium 437 Clindamycin 438 Clioquinol; at all strengths 439 Clobazam 440 Clobetasol 441 Clobetasone; except when specified elsewhere in this schedule 442 Clocortolone 443 Clodronic acid 444 Clofarabine 445 Clofazimine 446 Clofenamide 447 Clofibrate 16 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 448 Clomiphene 449 Clomipramine 450 Clomocycline 451 Clonazepam 452 Clonidine 453 Clopamide 454 Clopidogrel 455 Clorexolone 456 Clorprenaline 457
 Clostebol 458 Clotiazepam 459 Clotrimazole; except in medicines for vaginal or external use 460 Cloxacillin 461 Cloxazolam 462 Clozapine 463 Cobalt 464 Cobicistat 465 Cocaine; except when specified elsewhere in this schedule 466 Codeine; except when specified elsewhere in this schedule 467 Co-dergocrine 468 Colaspase 469 Colchicine 470 Colchicum 471 Colecalciferol; in medicines containing more than 25 micrograms per recom- mended daily dose except in parenteral nutrition replacement preparations 472 Colestipol 473
 Colestyramine 474 Colfosceril 475 Colistin 476 Collagen; in injections or implants for tissue augmentation or cosmetic use 477 Collagenase clostridium histolyticum 478 Conium maculatum; at all strengths 479 Convallaria keiski 480 Convallaria majalis 481 Corifollitropin alfa 17 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 482 Coronilla spp 483 Corticosterone 484 Corticotrophin 485 Cortisone and other steroidal hormones of the adrenal cortex; except when spe- cified elsewhere in this schedule; except adrenal extract for dermal use in med- icines containing 0.02% or less of ketosteroids 486 Cotarnine; at all strengths 487 Co-trimoxazole 488 Coumarin 489 Crizotinib 490 Crofelemer 491 Crotalaria spp; at all strengths 492 Croton tiglium; except in medicines containing 1 milligram or less per litre or per kilogram 493 Crystal violet 494 Curare 495 Cyclandelate 496 Cyclizine; except when specified elsewhere in this schedule 497 Cyclobenzaprine 498 Cyclofenil 499 Cycloheximide 500 Cyclopenthiazide 501 Cyclopentolate; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 502 Cyclophosphamide 503 Cyclopropane 504 Cycloserine 505 Cyclosporin 506 Cyclothiazide 507 Cycrimine 508 Cymarin 509 Cynoglossum spp; at all strengths 510 Cyproheptadine; except for oral use 511 Cyproterone 512 Cysteamine 18 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 513 Cytarabine 514 Dabigatran 515 Dabrafenib
 mesilate 516 Dacarbazine 517 Daclizumab 518 Dactinomycin 519 Dalfopristin 520 Dalteparin 521 Danaparoid 522 Danazol 523 Danthron 524 Dantrolene 525 Dapagliflozin 526 Dapoxetine 527 Dapsone 528 Daptomycin 529 Darbepoetin 530 Darifenacin 531 Darunavir 532 Dasabuvir 533 Dasatinib 534 Datura spp; except for oral use when specified elsewhere in this schedule; ex- cept datura stramonium or datura tatula for smoking or burning 535 Daunorubicin 536 Deanol 537 Debrisoquine 538 Decamethonium 539 Deferasirox 540 Deferiprone
 541 Deflazacort 542 Degarelix 543 Dehydrochloromethyltestosterone 544 Dehydrocorticosterone 545 Delavirdine 546 Delorazepam 19 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 547 Demecarium 548 Demeclocycline 549 Denosumab 550 Deoxycortone 551 Deoxyribonuclease; except for external use 552 Desferrioxamine 553 Desflurane 554 Desipramine 555 Desirudin 556 Deslanoside 557 Desloratadine; except for oral use 558 Deslorelin 559 Desmopressin 560 Desogestrel 561 Desonide 562 Desoximetasone 563 Desvenlafaxine 564 Dexamethasone 565 Dexamfetamine 566 Dexchlorpheniramine; except when specified elsewhere in this schedule 567 Dexfenfluramine 568 Dexmedetomidine 569 Dextromethorphan; except when specified elsewhere in this schedule 570 Dextromoramide 571 Dextropropoxyphene 572 Dextrorphan 573 Di-iodohydroxy quinoline; except for vaginal use 574 Di-isopropylamine dichloroacetate 575 Diazepam 576 Diazoxide 577 Dibenzepin 578 Dibotermin 579 Dibrompropamidine; except for ophthalmic use 580 Dichloralphenazone 581 Dichlorophen 20 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 582 Dichlorphenamide 583 Diclofenac; in preparations for the treatment of solar keratosis; except when specified elsewhere in this schedule; except in preparations for external use other than for the treatment of solar keratosis 584 Dicloxacillin 585 Dicyclomine 586 Didanosine 587 Dienoestrol 588 Dienogest 589 Diethazine 590 Diethylcarbamazine 591 Diethylstilbestrol 592 Diflorasone
 593 Diflucortolone 594 Diflunisal 595 Digitalis lanata 596 Digitalis purpurea 597 Digitoxin 598 Digoxin 599 Digoxin-specific antibody fragment 600 Dihydralazine 601 Dihydrocodeine 602 Dihydroergotoxine 603 Dihydrolone 604 Dihydrotachysterol 605 Diltiazem 606 Dimenhydrinate; except when specified elsewhere in this schedule 607 Dimercaprol 608 Dimethandrostanolone 609 Dimethazine 610 Dimethindene; except for oral use 611 Dimethothiazine 612 Dimethoxanate 613 Dimethyl fumarate 614 Dimethyl sulphoxide 21
 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 615 Dinitrocresols 616 Dinitronaphthols 617 Dinitrophenols 618 Dinitrothymols 619 Dinoprost 620 Dinoprostone 621 Diperodon 622 Diphemanil; except for dermal use 623 Diphenhydramine; except when specified elsewhere in this schedule 624 Diphenidol 625 Diphenoxylate; except when specified elsewhere in this schedule 626 Diphenylpyraline 627 Diphtheria, tetanus and pertussis (acellular, component) vaccine; except when administered in a single dose to a person 18 years of age or over by a registered pharmacist who has successfully completed a vaccinator training course ap- proved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health 628 Diphtheria toxoid 629 Diphtheria vaccine 630 Dipivefrin 631 Dipyridamole 632 Dirithromycin 633 Disopyramide 634 Distigmine 635 Disulfiram 636 Disulphamide 637 Ditiocarb 638 Dobutamine 639 Docetaxel 640 Dofetilide 641 Dolasetron 642 Dolutegravir 643 Domperidone 644 Donepezil 645 Dopamine 22 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 646 Dopexamine 647 Doripenem 648 Dornase 649 Dorzolamide 650 Dothiepin 651 Doxantrazole 652 Doxapram 653 Doxazosin 654 Doxepin 655 Doxorubicin 656 Doxycycline 657 Doxylamine; except when specified elsewhere in this schedule 658 Dronedarone 659 Droperidol 660 Drospirenone 661 Drostanolone 662 Drotrecogin 663 Duboisia leichhardtii; except when specified elsewhere in this schedule
 664 Duboisia myoporides; except when specified elsewhere in this schedule 665 Dulcin; at all strengths 666 Duloxetine 667 Dutasteride 668 Dydrogesterone 669 Econazole; except in medicines for vaginal or dermal use 670 Ecothiopate 671 Ectylurea 672 Eculizumab 673 Edetic acid; in medicines containing more than 0.25%; except in contact lens preparations; except dicobalt edetate for the treatment of cyanide poisoning 674 Edoxudine 675 Edrophonium 676 Efalizumab 677 Efavirenz 678 Eflornithine 679 Eletriptan 23
 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 680 Eltrombopag olamine 681 Elvitegravir 682 Emepronium 683 Emetine; in medicines containing more than 0.2% 684 Empagliflozin 685 Emtricitabine 686 Enalapril 687 Enestebol 688 Enflurane 689 Enfuvirtide 690 Enobosarm 691 Enoxacin 692 Enoxaparin 693 Enoximone 694 Enprostil 695 Entacapone 696 Entecavir 697 Enzalutamide 698 Ephedrine 699 Epicillin 700 Epinastine 701 Epirubicin 702 Epitiostanol 703 Eplerenone 704 Epoetins 705 Epoprostenol 706 Eprosartan 707 Eptifibatide 708 Ergocalciferol; in medicines containing more than 25 micrograms per recom- mended daily dose 709 Ergometrine 710 Ergot 711 Ergotamine 712 Ergotoxine 713 Eribulin 24 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 714 Erlotinib 715 Ertapenem 716 Erysimum spp; except in medicines containing 1 milligram or less per litre or per kilogram 717 Erythromycin 718 Erythropoietin 719 Escitalopram 720 Esmolol 721 Esomeprazole 722 Estazolam 723 Estramustine 724 Estropipate 725 Etanercept 726 Ethacrynic acid 727 Ethambutol 728 Ethamivan 729 Ethanolamine; for injection 730 Ethchlorvynol 731 Ether; for anaesthesia 732 Ethinamate 733 Ethinyloestradiol 734 Ethionamide 735 Ethisterone 736 Ethoglucid 737 Ethoheptazine 738 Ethopropazine 739 Ethosuximide 740 Ethotoin 741 Ethoxzolamide 742 Ethyl chloride; for inhalation 743 Ethyl loflazepate 744 Ethyldienolone 745 Ethylhexanediol; at all strengths 746 Ethyloestrenol 747 Ethynodiol 25 Schedule
 Medicines Amendment Regulations (No 2) 2015 2015/180 748 Etidocaine 749 Etidronic acid; except in medicines for external use containing 1% or less 750 Etilefrine 751 Etodolac 752 Etofenamate; except for external use 753 Etonogestrel 754 Etoposide 755 Etoricoxib 756 Etravirine 757 Etretinate 758 Everolimus 759 Exemestane 760 Exenatide 761 Ezetimibe 762 Factor VIII inhibitor bypassing fraction 763 Famciclovir; except when specified elsewhere in this schedule 764 Famotidine; except when specified elsewhere in
 this schedule 765 Fampridine 766 Farfugium japonicum; at all strengths 767 Febuxostat 768 Felbinac; except for external use 769 Felodipine 770 Felypressin; except when combined with a local anaesthetic and used in prac- tice by a dental therapist registered with the Dental Council 771 Fenbufen 772 Fenclofenac 773 Fenfluramine 774 Fenofibrate 775 Fenoldopam 776 Fenoprofen 777 Fenoterol 778 Fenpipramide 779 Fenpiprane 780 Fentanyl 781 Ferric carboxymaltose 26 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 782 Fexofenadine; except for oral use 783 Fibrin 784 Fibrinolysin; except for external use 785 Fidaxomicin 786 Filgrastim 787 Finasteride 788 Fingolimod 789 Flecainide 790 Fleroxacin 791 Floctafenine 792 Fluanisone 793 Fluclorolone 794 Flucloxacillin 795 Fluconazole; except when specified elsewhere in this schedule 796 Flucytosine 797 Fludarabine 798 Fludiazepam 799 Fludrocortisone 800 Flufenamic acid 801 Flumazenil 802 Flumethasone 803 Flumethiazide 804 Flunisolide 805 Flunitrazepam 806 Fluocinolone 807 Fluocinonide 808 Fluocortin 809 Fluocortolone 810 Fluorescein; for injection 811 Fluorides; for internal use in medicines containing more than 0.5 milligrams per dose unit except in medicines containing 15 milligrams or less per litre or per kilogram; except in parenteral nutrition replacement preparations; for exter- nal use in medicines containing more than 5.5 grams per litre or per kilogram except when supplied to a dental professional registered
 with the Dental Coun- cil 812 Fluorometholone 27 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 813 Fluorouracil 814 Fluoxetine 815 Fluoxymesterone 816 Flupenthixol 817 Fluphenazine 818 Flurandrenolone 819 Flurazepam 820 Flurbiprofen; except in locally acting oromucosal preparations containing 10 milligrams or less per dosage unit 821 Fluroxene 822 Fluspirilene 823 Flutamide 824 Fluticasone; except when specified elsewhere in this schedule 825 Fluvastatin 826 Fluvoxamine 827 Folic acid; for
 injection except in parenteral nutrition replacement preparations 828 Folinic acid; for injection 829 Follicle-stimulating hormone; except in medicines containing 100 micrograms or less per litre or per kilogram 830 Follistatin 831 Follitropin 832 Fomivirsen 833 Fondaparinux 834 Formebolone 835 Formestane 836 Formoterol 837 Fosamprenavir 838 Fosaprepitant 839 Foscarnet 840 Fosfestrol 841 Fosinopril 842 Fosphenytoin 843 Fotemustine 844 Framycetin 845 Fulvestrant 28 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 846 Furaltadone 847 Furazabol 848 Furazolidone 849 Furosemide 850 Fusidic acid 851 Gabapentin 852 Galantamine 853 Galanthus spp 854 Gallamine 855 Galsulfase 856 Ganciclovir 857 Ganirelix 858 Gatifloxacin 859 Gefitinib 860 Gemcitabine 861 Gemeprost 862 Gemfibrozil 863 Gemifloxacin 864 Gemtuzumab ozogamicin 865 Gentamicin 866 Gestodene 867 Gestonorone 868 Gestrinone 869 Ghrelin 870 Gitalin 871 Glatiramer acetate 872 Glibenclamide 873 Glibornuride 874 Gliclazide 875 Glimepiride 876 Glipizide 877 Glisoxepide 878 Glutathione; for injection 879 Glyceryl trinitrate; for injection; for transdermal use; except in medicines con- taining 100 micrograms or less per litre or per kilogram 29 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 880 Glycopyrronium 881 Glymidine 882 Golimumab 883 Gonadorelin 884 Gonadotrophic hormones; except when specified elsewhere in this schedule 885 Goserelin 886 Gramicidin 887 Granisetron 888 Grepafloxacin 889
 Griseofulvin 890 Guaiphenesin; for oral use in medicines containing more than 2% or 200 milli- grams per dose form except when specified elsewhere in this schedule; except for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer’s original pack containing not more than 10 days’ supply 891 Guanabenz 892 Guanethidine 893 Guanidine 894 Hachimycin 895 Haematin 896 Haemophilus influenzae vaccine; except in oral vaccines for the
 prophylaxis of bacterial complications of colds 897 Halazepam 898 Halcinonide 899 Halofantrine 900 Halofenate 901 Haloperidol; except in medicines containing 1 milligram or less per litre or per kilogram 902 Halothane 903 Haloxazolam 904 Halquinol; for internal use 905 Heliotropium spp; at all strengths 906 Hemerocallis 907 Heparins; for internal use; except when present as an excipient 908 Hepatitis A vaccine 909 Hepatitis B vaccine 30 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 910 Hetacillin 911 Hexachlorophane; in medicines containing more than 3% 912 Hexamethonium 913 Hexarelin 914 Hexetidine; for internal use 915 Hexobendine 916 Hexocyclium 917 Hexoprenaline 918 Histamine; in medicines containing more than 0.5% 919 Homatropine 920 Human chorionic gonadotrophin; except in pregnancy test kits 921 Human growth hormone secretagogues 922 Human papillomavirus vaccine 923 Human protein C 924 Hyaluronic acid; in injections or implants for tissue augmentation or cosmetic use 925 Hydralazine 926 Hydrargaphen 927 Hydrochlorothiazide 928 Hydrocortisone; except when specified elsewhere in this schedule 929 Hydrocyanic acid; except when specified elsewhere in this schedule; except in medicines containing 1 microgram or less per litre or per kilogram 930 Hydroflumethiazide 931 Hydromorphone 932 Hydroquinone; except in medicines for external use containing 2% or less 933 Hydroxychloroquine 934 Hydroxyephedrine 935 Hydroxyphenamate 936 Hydroxyprogesterone 937
 Hydroxystenozol 938 Hydroxyurea 939 Hydroxyzine 940 Hylan polymer; in injections or implants for tissue augmentation or cosmetic use 31 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 941 Hyoscine; except when specified elsewhere in this schedule; except in medi- cines containing 300 micrograms or less per litre or per kilogram 942 Hyoscine butylbromide; except when specified elsewhere in this schedule 943 Hyoscyamine; except when specified elsewhere in this schedule; except in medicines
 containing 300 micrograms or less per litre or per kilogram 944 Hyoscyamus niger; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less of total solanaceous alkaloids per litre or per kilogram 945 Hypothalamic releasing factors 946 Hypromellose; for injection; except in intraocular viscoelastic products 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 Ibandronic acid Ibogaine Ibritumomab tiuxetan Ibrutinib Ibufenac Ibuprofen; except when specified elsewhere in this schedule Ibuterol Ibutilide Icatibant Idarubicin Idoxuridine; except for dermal use in medicines containing 0.5% or less Idursulfase Ifosfamide Iloprost Imatinib Imiglucerase Imipenem Imipramine Imiquimod Immunoglobulins Indacaterol Indapamide Indinavir Indomethacin; except for external use in medicines containing 1% or less; ex- cept in medicines containing 1 milligram or less per litre or per kilogram 971 Indoprofen 32 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 Indoramin Infliximab Influenza and coryza vaccines; for injection; for nasal use Influenza vaccine; except when administered to a person 18 years of age or over by a registered pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the
 immunisation standards of the Ministry of Health Ingenol mebutate Insulin-like growth factors; except when specified elsewhere in this schedule Insulins Interferons Interleukins Iodothiouracil Ipamorelin Ipecacuanha; except in medicines containing less than 0.2% of emetine Ipilimumab Ipratropium; except for nasal use Ipriflavone Iprindole Iproniazid Irbesartan Irinotecan Iron; for injection except in parenteral nutrition replacement preparations Isoaminile Isoamyl nitrite Isobutyl nitrite Isocarboxazid Isoconazole;
 except in medicines for vaginal or dermal use Isoetarine Isoflurane Isometheptene 1000 Isoniazid 1001 Isoprenaline 1002 Isoprinosine 1003 Isopropamide; except for dermal use in preparations containing 2% or less 33 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1004 Isosorbide dinitrate 1005 Isosorbide mononitrate 1006 Isotretinoin 1007 Isoxicam 1008 Isoxsuprine 1009 Isradipine 1010 Itraconazole 1011 Ivabradine 1012 Ivacaftor 1013 Ivermectin 1014 Ixabepilone 1015 Japanese encephalitis vaccine 1016 Juniperus sabina; at all strengths 1017 Kanamycin 1018 Ketamine 1019 Ketanserin 1020 Ketazolam 1021 Ketoconazole; except for dermal use 1022 Ketoprofen; except when specified elsewhere in this schedule; except for der- mal use 1023 Ketorolac 1024 Ketotifen; except for ophthalmic use in medicines containing 0.025% or less 1025 Khellin 1026 Labetalol 1027 Lacidipine 1028 Lacosamide 1029 Lamivudine 1030 Lamotrigine 1031 Lanatosides 1032 Lanreotide 1033 Lansoprazole; except when specified elsewhere in this schedule 1034 Lanthanum 1035 Lapatinib 1036 Laronidase-rch 1037 Laropiprant 34 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1038 Latamoxef 1039 Latanoprost 1040 Laudexium 1041 Lauromacrogols; for injection 1042 Lead 1043 Ledipasvir 1044 Lefetamine 1045 Leflunomide 1046 Lenalidomide 1047 Lenograstim 1048 Lepirudin 1049 Leptazol 1050 Lercanidipine 1051 Letrozole 1052 Leucovorin; for injection 1053 Leuprorelin 1054 Levallorphan 1055 Levamisole 1056
 Levetiracetam 1057 Levobunolol 1058 Levobupivacaine 1059 Levocabastine; except for nasal or ophthalmic use 1060 Levocetirizine; except for oral use 1061 Levodopa 1062 Levomepromazine 1063 Levonorgestrel; except when specified elsewhere in this schedule; except in medicines for use as emergency post-coital contraception when sold by nurses recognised by their professional body as having competency in the field of sex- ual and reproductive health 1064 Levosimendan 1065 Lidoflazine 1066 Lignocaine; for
 injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatrists Board or dental therapist registered with the Dental Council; for oral use except in throat loz- enges containing 30 milligrams or less per dose form; for ophthalmic use ex- 35 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 cept when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for external use in medicines containing more than 10% 1067 Ligularia dentata; at all strengths 1068 Linagliptin 1069 Lincomycin 1070 Lindane; except for external use in medicines containing 2% or less 1071 Linezolid 1072 Liothyronine 1073 Liraglutide 1074 Lisinopril 1075 Lisuride 1076 Lithium; except when specified elsewhere in this schedule; except when pres- ent as an excipient in dermal medicines containing 0.25% or less 1077 Lixisenatide 1078 Lodoxamide; except in medicines for ophthalmic use 1079 Lofexidine 1080 Lomefloxacin 1081 Lomustine 1082 Loperamide; except when specified elsewhere in this schedule 1083 Lopinavir 1084 Loprazolam 1085 Loracarbef 1086 Loratadine; except for oral use 1087 Lorazepam 1088 Lormetazepam 1089 Losartan 1090 Loteprednol 1091 Lovastatin; except when present as an unmodified, naturally occurring sub- stance in a food that has not been subject to a manufacturing process other than heating, freezing,
 drying, preserving, bottling, canning, or packaging in retort pouches 1092 Loxapine 1093 Lumefantrine 1094 Lumiracoxib 1095 Lurasidone 36 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1096 Luteinising hormone 1097 Lymecycline 1098 Macitentan 1099 Mafenide 1100 Mannomustine 1101 Maprotiline 1102 Maraviroc 1103 Mazindol 1104 Measles vaccine 1105 Mebanazine 1106 Mebeverine 1107 Mebhydrolin 1108 Mebolazine 1109 Mebutamate 1110 Mecamylamine 1111 Mecasermin 1112 Mecillinam 1113 Meclocycline 1114
 Meclofenamate 1115 Meclofenoxate 1116 Meclozine; except when specified elsewhere in this schedule 1117 Medazepam 1118 Medigoxin 1119 Medroxyprogesterone 1120 Medrysone 1121 Mefenamic acid; except when specified elsewhere in this schedule 1122 Mefloquine 1123 Mefruside 1124 Megestrol 1125 Melagatran 1126 Melanocyte stimulating compounds 1127 Melatonin 1128 Melengestrol 1129 Melia azedarach; at all strengths 1130 Meloxicam 37 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1131 Melphalan 1132 Memantine 1133 Meningococcal vaccine; except when administered to a person 16 years of age or over by a registered pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health 1134 Menotrophin 1135 Mepacrine 1136 Mepenzolate 1137 Mephenesin 1138 Mephentermine 1139 Mepindolol 1140 Mepitiostane 1141 Mepivacaine 1142 Meprobamate 1143 Meptazinol 1144 Mepyramine; except when specified elsewhere in this schedule 1145 Mequitazine 1146 Mercaptomerin 1147 Mercaptopurine 1148 Mercurochrome; except when specified elsewhere in this schedule 1149 Mercury; except when specified elsewhere in this schedule; except in medi- cines containing 1 milligram or less per litre or per kilogram 1150 Meropenem 1151 Mersalyl 1152 Mesabolone 1153 Mesalazine 1154 Mesna 1155 Mestanolone 1156 Mesterolone 1157 Mestranol 1158 Metamfetamine 1159 Metandienone 1160 Metaraminol
 1161 Metenolone 38 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1162 Metergoline 1163 Metformin 1164 Methacholine 1165 Methacycline 1166 Methadone 1167 Methallenoestril 1168 Methandriol 1169 Methanthelinium 1170 Methazolamide 1171 Methdilazine; except for oral use 1172 Methicillin 1173 Methimazole 1174 Methisazone 1175 Methixene 1176 Methocarbamol 1177 Methohexitone 1178 Methoin 1179 Methotrexate 1180 Methoxamine; except for external use 1181 Methoxsalen 1182 Methoxyflurane 1183
 Methsuximide 1184 Methyclothiazide 1185 Methyl aminolevulinate 1186 Methyl androstanolone 1187 Methyl clostebol 1188 Methyl mercury; except in medicines containing 300 micrograms or less per li- tre or per kilogram 1189 Methyl salicylate; for internal use except when present as an excipient in medi- cines containing 1.04% or less per dose form 1190 Methyl trienolone 1191 Methyldopa 1192 Methylene blue; for injection 1193 Methylergometrine 1194 Methylnaltrexone 39 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1195 Methylpentynol 1196 Methylphenidate 1197 Methylphenobarbital 1198 Methylprednisolone 1199 Methyltestosterone 1200 Methylthiouracil 1201 Methyprylon 1202 Methysergide 1203 Metoclopramide; except when specified elsewhere in this schedule 1204 Metolazone 1205 Metoprolol 1206 Metribolone 1207 Metrifonate 1208 Metronidazole 1209 Metyrapone 1210 Mexiletine 1211 Mezlocillin 1212 Mianserin 1213 Mibefradil 1214 Mibolerone 1215 Micafungin 1216 Miconazole; except when specified elsewhere in this schedule; except in medi- cines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board 1217 Midazolam 1218 Midodrine 1219 Mifepristone 1220 Miglitol 1221 Miglustat 1222 Milrinone 1223 Minocycline 1224 Minoxidil; except for dermal use in medicines containing 5% or less 1225 Mirabegron 1226 Mirtazapine 1227 Misoprostol 40 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1228 Mitobronitol 1229 Mitomycin
 1230 Mitoxantrone 1231 Mitragyna speciosa 1232 Mitragynine 1233 Mivacurium 1234 Moclobemide 1235 Modafinil 1236 Molgramostim 1237 Molindone 1238 Mometasone; except when specified elsewhere in this schedule 1239 Monobenzone 1240 Monoclonal antibodies; except in pregnancy test kits 1241 Montelukast 1242 Moperone 1243 Morazone 1244 Moricizine 1245 Morphine; except when specified elsewhere in this schedule 1246 Motrazepam 1247 Motretinide 1248 Moxifloxacin 1249 Mumps vaccine 1250 Mupirocin 1251 Muraglitazar 1252
 Muromonab 1253 Mustine 1254 Mycophenolic acid 1255 Nabilone 1256 Nabumetone 1257 Nadolol 1258 Nadroparin 1259 Nafarelin 1260 Naftidrofuryl 1261 Nalbuphine 1262 Nalidixic acid 41 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1263 Nalmefene 1264 Nalorphine 1265 Naloxone 1266 Naltrexone 1267 Nandrolone 1268 Naproxen; except when specified elsewhere in this schedule 1269 Naratriptan 1270 Natalizumab 1271 Natamycin 1272 Nateglinide 1273 Nebacumab 1274 Nebivolol 1275 Nedocromil 1276 Nefazodone 1277 Nefopam 1278 Nelfinavir 1279 Neomycin 1280 Neostigmine 1281 Nepafenac 1282 Nerium oleander 1283 Nesiritide 1284 Netilmicin 1285 Nevirapine 1286 Nialamide 1287 Nicardipine 1288 Nicergoline 1289 Nicofuranose 1290 Nicorandil 1291 Nicotine; for nasal use except when sold from a smoking cessation clinic run under the auspices of a registered medical practitioner; in medicines other than for smoking cessation 1292 Nicotinic acid except nicotinamide; in medicines containing more than 250 milligrams per dose form 1293 Nicoumalone 1294 Nifedipine 42 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1295 Nifenazone 1296 Nikethamide 1297 Nilotinib 1298 Nilutamide 1299 Nimesulide 1300 Nimetazepam 1301 Nimodipine 1302 Nimorazole 1303 Nintedanib 1304 Niridazole 1305 Nisoldipine 1306 Nitisinone 1307 Nitrazepam 1308 Nitrendipine 1309 Nitric oxide 1310 Nitrofurantoin 1311 Nitrofurazone 1312 Nitrous oxide; when supplied for inhalation 1313 Nitroxoline 1314 Nizatidine;
 except when specified elsewhere in this schedule 1315 Nomegestrol 1316 Nomifensine 1317 Noradrenaline 1318 Norandrostenolone 1319 Norbolethone 1320 Norclostebol 1321 Nordazepam 1322 Norelgestromin 1323 Norethandrolone 1324 Norethisterone 1325 Norfloxacin 1326 Norgestrel 1327 Noribogaine 1328 Normethandrone 1329 Nortriptyline 43 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1330 Noxiptyline 1331 Nux vomica; except in medicines containing 1 milligram or less per litre or per kilogram of
 strychnine 1332 Nystatin; except when specified elsewhere in this schedule; except in medi- cines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board 1333 Obinutuzumab 1334 Ocriplasmin 1335 Octamylamine 1336 Octatropine 1337 Octreotide 1338 Octyl nitrite 1339 Oestradiol; except in medicines containing 10 micrograms or less per litre or per kilogram 1340 Oestriol 1341 Oestrogens 1342 Oestrone; except in medicines containing 1 milligram or less per litre or per kilogram 1343 Ofatumumab 1344 Ofloxacin 1345 Olanzapine 1346 Oleandomycin 1347 Oleandrin 1348 Olmesartan 1349 Olodaterol 1350 Olopatadine 1351 Olsalazine 1352 Omalizumab 1353 Ombitasvir 1354 Omeprazole; except when specified elsewhere in this schedule 1355 Ondansetron 1356 Opipramol 1357 Opium; except when specified elsewhere in this schedule 1358 Orciprenaline 1359 Orlistat; except in medicines for weight control containing 120 milligrams or less per dose form 44 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1360 Ornidazole 1361 Ornipressin 1362 Orphenadrine 1363 Orthopterin 1364 Oseltamivir; except when specified elsewhere in this schedule 1365 Ouabain 1366 Ovandrotone 1367 Oxabolone 1368 Oxacillin 1369 Oxaliplatin 1370 Oxandrolone 1371 Oxaprozin 1372 Oxazepam 1373 Oxazolam 1374 Oxcarbazepine 1375 Oxedrine; in medicines containing more than 30 milligrams per recommended daily dose 1376 Oxetacaine; except for internal use 1377 Oxiconazole;
 except when specified elsewhere in this schedule 1378 Oxitropium 1379 Oxolamine 1380 Oxolinic acid 1381 Oxpentifylline 1382 Oxprenolol 1383 Oxybuprocaine; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 1384 Oxybutynin 1385 Oxycodone 1386 Oxymesterone 1387 Oxymetholone 1388 Oxyphenbutazone 1389 Oxyphencyclimine 1390 Oxyphenisatin; at all strengths 1391 Oxyphenonium 1392 Oxytetracycline 45 Schedule Medicines Amendment Regulations (No 2) 2015
 2015/180 1393 Oxytocin; except in medicines containing 1 microgram or less per litre or per kilogram 1394 Paclitaxel 1395 Palifermin 1396 Paliperidone 1397 Palivizumab 1398 Palonosetron 1399 Pamaquin 1400 Pamidronic acid 1401 Pancreatic enzymes; in medicines containing more than 20 000 BP units of li- pase activity 1402 Pancuronium 1403 Panitumumab 1404 Pantoprazole; except when specified elsewhere in this schedule 1405 Papaveretum 1406 Papaverine; for injection 1407 Paracetamol; except when specified elsewhere in this schedule 1408 Paraldehyde 1409 Paramethadione 1410 Paramethasone 1411 Parecoxib 1412 Paricalcitol 1413 Paromomycin 1414 Paroxetine 1415 Pasireotide 1416 Pazopanib 1417 Pecazine 1418 Pefloxacin 1419 Pegaptanib 1420 Pegfilgrastim 1421 Peginterferon 1422 Pegvisomant 1423 Pemetrexed 1424 Pemoline 1425 Pempidine 46 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1426 Penbutolol 1427 Penciclovir; except for external use for the treatment of herpes labialis 1428 Penicillamine 1429 Pentaerythrityl tetranitrate 1430 Pentagastrin 1431 Pentamethonium 1432 Pentamidine 1433 Pentazocine 1434 Penthienate 1435 Pentolinium 1436 Pentosan polysulfate sodium 1437 Pentoxifylline 1438 Perampanel 1439 Pergolide 1440 Perhexiline 1441 Pericyazine 1442 Perindopril 1443 Permethrin; in medicines containing more than 5% 1444 Perphenazine 1445 Pertussis antigen 1446 Pertussis (whooping cough) vaccine 1447 Pertuzumab 1448 Pethidine 1449 Phenacemide 1450 Phenacetin;
 except when present as an excipient 1451 Phenaglycodol 1452 Phenazone; except for external use 1453 Phenazopyridine 1454 Phenelzine 1455 Pheneticillin 1456 Phenformin 1457 Phenglutarimide 1458 Phenindione 1459 Pheniramine; except when specified elsewhere in this schedule 1460 Phenisatin 47 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1461 Phenobarbital 1462 Phenol; for injection 1463 Phenolphthalein 1464 Phenoperidine 1465 Phenoxybenzamine 1466 Phenoxymethylpenicillin 1467 Phensuximide 1468
 Phentermine 1469 Phenthimentonium 1470 Phentolamine 1471 Phenylbutazone 1472 Phenylephrine; except when specified elsewhere in this schedule 1473 Phenylpropanolamine 1474 Phenyltoloxamine 1475 Phenytoin 1476 Pholcodine; except when specified elsewhere in this schedule 1477 Phosphodiesterase type 5 inhibitors; except when present as an unmodified, naturally occurring substance; except when specified elsewhere in this sched- ule 1478 Phthalylsulfathiazole 1479 Physostigmine 1480 Picric acid 1481 Picrotoxin 1482 Pilocarpine; except in medicines containing 0.025% or less 1483 Pimecrolimus 1484 Pimozide 1485 Pinacidil 1486 Pinazepam 1487 Pindolol 1488 Pioglitazone 1489 Pipecuronium 1490 Pipemidic acid 1491 Pipenzolate 1492 Piperacillin 1493 Piperidine 48 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1494 Piperidolate 1495 Pipobroman 1496 Pipothiazine 1497 Pipradrol 1498 Piracetam 1499 Pirbuterol 1500 Pirenoxine 1501 Pirenzepine 1502 Piretanide 1503 Piroxicam; except for external use 1504 Pirprofen 1505 Pitavastatin 1506 Pituitary hormones 1507 Pivampicillin 1508 Pizotifen 1509 Plerixafor 1510 Plicamycin 1511 Pneumococcal vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds 1512 Podophyllotoxin; for internal use; for external use for the treatment of anogeni- tal warts; for other external use in medicines containing more than 1%; except in medicines containing 1 milligram or less of podophyllin per litre or per kilo-
 gram 1513 Podophyllum emodi; for internal use; for external use for the treatment of ano- genital warts; for other external use in medicines containing more than 20% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram 1514 Podophyllum peltatum; for internal use; for external use for the treatment of anogenital warts; for other external use in medicines containing more than 20% of podophyllin; except in medicines containing 1 milligram or less of podo-
 phyllin per litre or per kilogram 1515 Polidexide 1516 Poliomyelitis vaccine 1517 Polyacrylamide; in injections or implants for tissue augmentation or cosmetic use 1518 Polyestradiol 49 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1519 Polylactic acid; in injections or implants for tissue augmentation or cosmetic use 1520 Polymyxin 1521 Polysulfated glycosaminoglycans; for injection except in intraocular viscoelas- tic products 1522 Polythiazide 1523 Pomalidomide 1524 Poractant alfa 1525 Posaconazole 1526 Potassium bromide 1527 Potassium perchlorate 1528 Practolol 1529 Pradofloxacin 1530 Pralatrexate 1531 Pralidoxime 1532 Pramipexole 1533 Pramocaine 1534 Prampine 1535 Prasterone 1536 Prasugrel 1537 Pravastatin 1538 Prazepam 1539 Praziquantel 1540 Prazosin 1541 Prednisolone 1542 Prednisone 1543 Pregabalin 1544 Pregnenolone 1545 Prenalterol 1546 Prenylamine 1547 Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist registered with the Dental Council; except when specified elsewhere in this schedule 1548 Primaquine 1549 Primidone 50 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1550 Probenecid 1551 Probucol 1552 Procainamide 1553 Procaine 1554 Procaine penicillin 1555 Procarbazine 1556 Prochlorperazine; except when specified elsewhere in this schedule; except when sold for the treatment of nausea associated with emergency contraception by pharmacists or nurses accredited to sell
 levonorgestrel for emergency con- traception 1557 Procyclidine; except for dermal use in medicines containing 5% or less 1558 Progesterone; except in medicines containing 1 milligram or less per litre or per kilogram 1559 Progestogens 1560 Proglumide 1561 Proguanil 1562 Prolintane 1563 Promazine 1564 Promethazine; except when specified elsewhere in this schedule 1565 Promoxolane 1566 Propafenone 1567 Propamidine; except for ophthalmic use 1568 Propanidid 1569 Propantheline 1570 Propetandrol 1571 Propionibacterium
 acnes 1572 Propofol 1573 Propranolol; except in medicines containing 1 milligram or less per litre or per kilogram 1574 Propylthiouracil 1575 Propyphenazone 1576 Proquazone 1577 Proscillaridin 1578 Prostaglandins 1579 Protamine 1580 Prothionamide 51 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1581 Prothipendyl 1582 Protirelin 1583 Protoveratrines 1584 Protriptyline 1585 Proxymetacaine; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 1586 Prucalopride 1587 Pseudoephedrine 1588 Pulmonaria spp; at all strengths 1589 Pyrazinamide 1590 Pyridinolcarbamate 1591 Pyridostigmine 1592 Pyridoxal; in medicines containing more than 200 milligrams per recommen- ded daily dose 1593 Pyridoxamine; in medicines containing more than 200 milligrams per recom- mended daily dose 1594 Pyridoxine; in medicines containing more than 200 milligrams per recommen- ded daily dose 1595 Pyrimethamine 1596 Pyrvinium 1597 Quazepam 1598 Quetiapine 1599 Quinagolide 1600 Quinapril 1601 Quinbolone 1602 Quinethazone 1603 Quinidine 1604 Quinine; except in medicines containing 50 milligrams or less per recommen- ded daily dose 1605 Quinisocaine 1606 Quinupristin 1607 Rabeprazole 1608 Rabies vaccine 1609 Raloxifene 1610 Raltegravir 1611 Raltitrexed 52 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1612 Ramipril 1613 Ranibizumab 1614 Ranitidine; except when specified elsewhere in this schedule; except in medi- cines
 containing 150 milligrams or less per dose unit when sold in the manu- facturer’s original pack containing not more than 7 days’ supply 1615 Rapacuronium 1616 Rasagiline 1617 Rasburicase 1618 Rauwolfia serpentina 1619 Rauwolfia vomitoria 1620 Razoxane 1621 Reboxetine 1622 Regorafenib 1623 Remestemcel-L 1624 Remifentanil 1625 Remoxipride 1626 Repaglinide 1627 Reserpine 1628 Retapamulin 1629 Reteplase 1630 Retigabine 1631 Ribavirin 1632 Ridaforolimus 1633 Rifabutin 1634 Rifampicin 1635 Rifamycin 1636
 Rifapentine 1637 Rifaximin 1638 Rilpivirine 1639 Riluzole 1640 Rimexolone 1641 Rimiterol 1642 Rimonabant 1643 Riociguat 1644 Risedronic acid 53 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1645 Risperidone 1646 Ritodrine 1647 Ritonavir 1648 Rituximab 1649 Rivaroxaban 1650 Rivastigmine 1651 Rizatriptan; except when specified elsewhere in this schedule 1652 Rocuronium 1653 Rofecoxib 1654 Roflumilast 1655 Rolitetracycline 1656 Romidepsin 1657 Romiplostim 1658 Ropinirole 1659 Ropivacaine 1660 Rosiglitazone 1661 Rosoxacin 1662 Rosuvastatin 1663 Rotavirus vaccine 1664 Rotigotine 1665 Roxibolone 1666 Roxithromycin 1667 Rubella vaccine 1668 Ruboxistaurin 1669 Rupatadine 1670 Ruxolitnib 1671 Sabadilla; except in preparations containing 10 milligrams or less of total alka- loids of schoenocaulon officinale per litre or per kilogram 1672 Safrole; for internal use except in medicines containing 0.1% or less 1673 Salbutamol 1674 Salcatonin 1675 Salmeterol 1676 Sapropterin 1677 Saquinavir 1678 Saxagliptin 54 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1679 Schoenocaulon officinale; except in preparations containing 10 milligrams or less of total alkaloids of schoenocaulon officinale per litre or per kilogram 1680 Scopolia carniolica 1681 Secbutabarbital 1682 Secobarbital 1683 Selective androgen receptor modulators 1684 Selegiline 1685 Selenium; except when specified elsewhere in this schedule; except for oral use in medicines containing 150
 micrograms or less per recommended daily dose; except for external use in medicines containing 3.5% or less of selenium sul- phide 1686 Selexipag 1687 Serelaxin 1688 Sermorelin 1689 Sertindole 1690 Sertraline 1691 Serum, dried human 1692 Sevelamer 1693 Sevoflurane 1694 Sex hormones and all substances having sex hormone activity 1695 Sialoepoetin 1696 Sibutramine 1697 Silandrone 1698 Sildenafil and its structural analogues; except sildenafil in medicines for oral use containing 100 milligrams or less per dose
 unit when sold in the manufac- turer’s original pack containing not more than 12 solid dosage units for the treatment of erectile dysfunction in males aged 35–70 years by a registered pharmacist who has successfully completed a training programme endorsed by the Pharmaceutical Society of New Zealand 1699 Silicones; for injection 1700 Siltuximab 1701 Silver sulfadiazine; except for external use in packs containing 50 grams or less 1702 Simeprevir 1703 Simvastatin 1704 Sirolimus 1705 Sisomicin 1706 Sitagliptin 55 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1707 Sitaxentan 1708 Sodium bromide 1709 Sodium cellulose phosphate; for internal use 1710 Sodium cromoglycate; except for nasal and ophthalmic use 1711 Sodium morrhuate; for injection 1712 Sodium nitroprusside 1713 Sodium phosphate; in oral laxative preparations 1714 Sodium polystyrene sulphonate 1715 Sodium tetradecyl sulphate; for injection 1716 Sofosbuvir 1717 Solasadine 1718 Solifenacin 1719 Somatostatin 1720 Somatropin 1721 Sontoquine 1722 Sorafenib 1723 Sotalol 1724 Sparfloxacin 1725 Sparteine 1726 Spectinomycin 1727 Spiramycin 1728 Spirapril 1729 Spironolactone 1730 Stanolone 1731 Stanozolol 1732 Staphylococcus aureus vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds 1733 Stavudine 1734 Stenbolone 1735 Steroid hormones 1736 Stilboestrol 1737 Stramonium; except for oral use when specified elsewhere in this schedule; ex- cept datura stramonium or datura
 tatula for smoking or burning 1738 Streptococcus beta-haemolyticus vaccine; except in oral vaccines for the pro- phylaxis of bacterial complications of colds 56 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1739 Streptodornase 1740 Streptokinase 1741 Streptomycin 1742 Strontium ranelate 1743 Strophanthins 1744 Strophanthus spp 1745 Strychnos spp; except in medicines containing 1 milligram or less per litre or per kilogram of strychnine 1746 Styramate 1747 Succimer 1748 Sufentanil 1749
 Sugammadex 1750 Sulbactam 1751 Sulconazole; except for dermal use 1752 Sulfacetamide; except for ophthalmic use in medicines containing 10% or less 1753 Sulfadiazine; except silver sulfadiazine for external use in pack sizes of 50 grams or less 1754 Sulfadimethoxine 1755 Sulfadimidine 1756 Sulfadoxine 1757 Sulfafurazole 1758 Sulfaguanidine 1759 Sulfamerazine 1760 Sulfamethizole 1761 Sulfamethoxazole 1762 Sulfamethoxydiazine 1763 Sulfamethoxypyridazine 1764 Sulfametrole 1765 Sulfamonomethoxine 1766 Sulfamoxole 1767 Sulfaphenazole 1768 Sulfapyridine 1769 Sulfasalazine 1770 Sulfathiazole 1771 Sulfatroxazole 57 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1772 Sulfinpyrazone 1773 Sulfomyxin 1774 Sulfonmethane 1775 Sulindac 1776 Sultamicillin 1777 Sulthiame 1778 Sumatriptan; except when specified elsewhere in this schedule 1779 Sunitinib 1780 Suprofen 1781 Sutilains 1782 Suxamethonium 1783 Suxethonium 1784 T cell receptor antibody 1785 Tacrine 1786 Tacrolimus 1787 Tadalafil and its structural analogues 1788 Tafluprost 1789 Taliglucerase alfa 1790 Tamoxifen 1791 Tamsulosin 1792 Tanacetum vulgare; in medicines containing more than 0.8% of oil of tansy 1793 Tapentadol 1794 Tasonermin 1795 Tazarotene 1796 Tazobactam 1797 Tegafur 1798 Tegaserod 1799 Teicoplanin 1800 Telaprevir 1801 Telbivudine 1802 Telithromycin 1803 Telmisartan 1804 Temazepam 1805 Temozolomide 1806 Temsirolimus 58 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1807
 Tenecteplase 1808 Teniposide 1809 Tenofovir 1810 Tenoxicam 1811 Terazosin 1812 Terbinafine; except in medicines for dermal use 1813 Terbutaline 1814 Terfenadine 1815 Teriflunomide 1816 Teriparatide 1817 Terlipressin 1818 Terodiline 1819 Teropterin 1820 Tesamorelin 1821 Testolactone 1822 Testosterone; except in medicines containing 1 milligram or less per litre or per kilogram 1823 Tetanus antitoxin 1824 Tetanus toxoid 1825 Tetanus vaccine 1826 Tetrabenazine 1827 Tetracosactrin 1828 Tetracycline 1829
 Tetraethylammonium 1830 Tetrahydrocannabinol 1831 Tetrazepam 1832 Tetroxoprim 1833 Thalidomide 1834 Thenyldiamine 1835 Theophylline; except in liquid form for oral use in medicines containing 2% or less 1836 Thevetia peruviana 1837 Thevetin 1838 Thiambutosine 1839 Thiazosulfone 59 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1840 Thiethylperazine 1841 Thioacetazone 1842 Thiocarlide 1843 Thioguanine 1844 Thiomesterone 1845 Thiopentone 1846 Thiopropazate 1847 Thioproperazine 1848 Thioridazine 1849 Thiotepa 1850 Thiothixene 1851 Thiouracil 1852 Thiourea; except in medicines containing 0.1% or less 1853 Thymoxamine 1854 Thyroid 1855 Thyrotrophin 1856 Thyrotrophin-releasing factor 1857 Thyroxine; except in medicines containing 10 micrograms or less per litre or per kilogram 1858 Tiagabine 1859 Tiaprofenic acid 1860 Tiaramide 1861 Tibolone 1862 Ticagrelor 1863 Ticarcillin 1864 Ticlopidine 1865 Tiemonium 1866 Tienilic acid 1867 Tigecycline 1868 Tigloidine 1869 Tiletamine 1870 Tilidine 1871 Tiludronic acid 1872 Timolol 1873 Tinidazole 60 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1874 Tinzaparin 1875 Tioconazole; except in medicines for vaginal or dermal use 1876 Tiotropium 1877 Tipepidine 1878 Tiprinavir 1879 Tirilazad 1880 Tirofiban 1881 Tobramycin 1882 Tocainide 1883 Tocilizumab 1884 Tolazamide 1885 Tolazoline 1886 Tolbutamide 1887 Tolcapone 1888 Tolfenamic acid 1889 Tolmetin 1890 Tolonium 1891 Tolpropamine 1892 Tolrestat 1893 Tolterodine
 1894 Tolvaptan 1895 Topiramate 1896 Topotecan 1897 Torasemide 1898 Toremifene 1899 Toxoids; for injection 1900 Tramadol 1901 Trametinib dimethyl sulfoxide 1902 Trandolapril 1903 Tranexamic acid 1904 Tranylcypromine 1905 Trastuzumab 1906 Trastuzumab emtansine 1907 Travoprost 1908 Trazodone 61 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1909 Trenbolone 1910 Treosulphan 1911 Treprostinil 1912 Trestolone 1913 Tretamine 1914 Tretinoin 1915 Triacetyloleandomycin 1916 Triamcinolone; except when
 specified elsewhere in this schedule 1917 Triamterene 1918 Triaziquone 1919 Triazolam 1920 Trichlormethiazide 1921 Trichloroacetic acid; except for external use in medicines containing 12.5% or less for the treatment of warts other than anogenital warts 1922 Trichloroethylene 1923 Trichodesma africana; at all strengths 1924 Triclofos 1925 Tricyclamol 1926 Tridihexethyl 1927 Trifluoperazine 1928 Trifluperidol 1929 Triflupromazine 1930 Trimeprazine; except when specified elsewhere in this schedule 1931 Trimetaphan 1932 Trimethoprim; except in medicines for oral use containing 300 milligrams or less per dose unit when sold in a pack of 3 solid dosage units to a woman aged 16–65 years for the treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the New Zealand Col- lege of Pharmacists’ training in the treatment of urinary tract infections 1933 Trimipramine 1934 Trimustine 1935 Trinitrophenol 1936 Trioxysalen 1937 Triparanol; at all strengths 1938 Triple antigen vaccine 1939 Triprolidine; except when specified elsewhere in this schedule 62 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 1940 Triptorelin 1941 Troglitazone 1942 Trometamol; for injection in medicines containing more than 3% 1943 Tropicamide; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 1944 Tropisetron 1945 Trovafloxacin 1946 Troxidone 1947 Tryptophan; in medicines containing more
 than 100 milligrams per recommen- ded daily dose except in parenteral nutrition replacement preparations 1948 Tuberculin 1949 Tuberculosis vaccine 1950 Tubocurarine 1951 Tulobuterol 1952 Typhoid vaccine 1953 Umeclidinium bromide 1954 Unoprostone 1955 Uracil 1956 Urapidil 1957 Urethane 1958 Urofollitropin 1959 Urokinase 1960 Ursodeoxycholic acid 1961 Ustekinumab 1962 Vaccines; except when specified elsewhere in this schedule 1963 Vaccinia virus vaccine 1964 Valaciclovir 1965 Valdecoxib 1966 Valganciclovir 1967
 Valnoctamide 1968 Valproic acid 1969 Valsartan 1970 Vancomycin 1971 Vandetanib 1972 Vardenafil and its structural analogues 63 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 1973 Varenicline 1974 Varicella vaccine; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed a vaccinator training course approved by the Minis- try of Health and who is complying with the immunisation standards of the Ministry of Health 1975 Vasopressin 1976 Vecuronium 1977 Vedolizumab 1978 Velaglucerase alfa 1979 Vemurafenib 1980 Venlafaxine 1981 Verapamil 1982 Veratrum spp 1983 Vernakalant 1984 Verteporfin 1985 Veruprevir 1986 Vidarabine 1987 Vigabatrin 1988 Vilanterol 1989 Vildagliptin 1990 Viloxazine 1991 Vinblastine 1992 Vincamine 1993 Vincristine 1994 Vindesine 1995 Vinflunine 1996 Vinorelbine 1997 Vinyl ether 1998 Virginiamycin 1999 Vismodegib 2000 Visnadine 2001 Vitamin A; for internal use in medicines containing more than 3 milligrams of retinol equivalents per recommended daily dose except in parenteral nutrition replacement preparations; for external use in medicines containing more than 1% 64 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 2002 Vitamin D; for internal use in medicines containing more than 25 micrograms per recommended daily dose except in parenteral nutrition replacement prepar- ations 2003 Voriconazole 2004 Vorinostat 2005
 Vortioxetine 2006 Warfarin 2007 Xamoterol 2008 Xanthinol nicotinate 2009 Ximelagatran 2010 Xipamide 2011 Yellow fever vaccine 2012 Yohimbine 2013 Zafirlukast 2014 Zalcitabine 2015 Zaleplon 2016 Zanamivir 2017 Zidovudine 2018 Zimeldine 2019 Zinc; for internal use in medicines containing more than 25 milligrams per rec- ommended daily dose; except for internal use in medicines containing 50 milli- grams or less and more than 25 milligrams per recommended daily dose in packs that have received the consent of the
 Minister or the Director-General to their distribution as general sale medicines, when sold in the manufacturer’s original pack and when labelled with a statement that the product may be dan- gerous if taken in large amounts or for long periods; except in parenteral nutri- tion replacement preparations 2020 Ziprasidone 2021 Zoledronic acid 2022 Zolmitriptan; except when specified elsewhere in this schedule 2023 Zolpidem 2024 Zonisamide 2025 Zopiclone 2026 Zoster immunoglobulin, human 2027 Zoxazolamine 2028 Zuclopenthixol 65 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 Part 2 Restricted medicines Adrenaline; in medicines containing 1% or less except in medicines for injec- tion containing 0.02% or less Alclometasone; for dermal use in medicines containing 0.05% or less and in packs containing not more than 30 grams that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack Aminophylline; for oral use in liquid form in medicines containing 2% or less Amorolfine; for external use in medicines containing more than 0.25% Aspirin; in slow-release forms; in enteric coated forms containing more than 300 milligrams per dose form; except when specified elsewhere in this sched- ule Azatadine; for oral use in adults and children over 2 years of age Azelastine; in medicines for ophthalmic use containing 0.05% or less Brompheniramine; for oral use in
 medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufac- turer’s original pack containing not more than 10 dosage units Buclizine; for oral use Butoconazole; for vaginal use Chloramphenicol; for ophthalmic use; except when sold in practice by an op- tometrist registered with the Optometrists and Dispensing Opticians Board Chlorbutol; in medicines containing more than 5%
 Chlorpheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufac- turer’s original pack containing not more than 10 dosage units Ciclopirox; for external use in medicines containing more than 2%; in prepar- ations for application to the nails containing more than 8% Cimetidine; in medicines for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’ supply Clemastine; for oral use Clobetasone; for dermal use in medicines containing 0.05% or less and in packs containing not more than 30 grams that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack 66 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 26 27 28 29 30 31 32 Clotrimazole; for vaginal use Codeine; in medicines for oral use containing not more than 15 milligrams of codeine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of codeine, when combined with 1 or more ac- tive ingredients in such a way that the substance cannot be recovered by readily
 applicable means or in a yield that would constitute a risk to health, for use as an analgesic and when sold in a pack of not more than 5 days’ supply, ap- proved by the Minister or the Director-General for distribution as a restricted medicine Cyclizine; for oral use other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units Cyproheptadine; for oral use
 Dexchlorpheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insom- nia; for oral use for the treatment of anxiety or insomnia when sold in the man- ufacturer’s original pack containing not more than 10 dosage units Di-iodohydroxy quinoline; for vaginal use Diclofenac; in solid dose form in medicines containing 25 milligrams or less and more than 12.5 milligrams per dose form in packs containing not more than 30 tablets or capsules Dimenhydrinate; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule Dimethindene; for oral use Diphenhydramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufac- turer’s original pack containing not more than 10 dosage units Dithranol Doxylamine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units Econazole; for vaginal use Erythrityl tetranitrate Famciclovir; in divided solid dosage forms for oral use containing 500 milli- grams or less for the treatment of recurrent herpes labialis when
 sold in the manufacturer’s original pack containing up to 3 dosage units 33 Flavoxate 67 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 Fluconazole; for oral use in medicines that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack containing 150 milligrams or less as a single dose for the treatment of vaginal candidiasis Fluorides; for external use in liquid form in medicines
 containing 5.5 grams or less and more than 1 gram per litre or per kilogram and when sold in packs ap- proved by the Minister or the Director-General for distribution as restricted medicines; for external use in non-liquid form in medicines containing 5.5 grams or less and more than 1 gram per litre or per kilogram, except in medi- cines containing 1.5 grams or less and more than 1 gram per litre or per kilo- gram; except when supplied to a dental professional registered with the Dental Council Glucagon; except in medicines containing 100 micrograms or less per litre or per kilogram Glyceryl trinitrate; for oral or sublingual use; for rectal use Guaiphenesin; for oral use in modified release form with a maximum recom- mended daily dose of not more than 2.4 grams when sold in the manufacturer’s original pack containing more than 10 days’ supply but not more than 30 days’ supply Haemophilus influenzae vaccine; in oral vaccines for the prophylaxis of bacte- rial complications of colds Hydrocortisone and hydrocortisone acetate but no other esters of hyrocorti- sone; for dermal use in medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base with no other active ingredient except an anti- fungal and in a quantity of 30 grams or less or 30 millilitres or less per contain- er; in rectal medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base and in combination with a local anaesthetic and in a quan- tity of 35 grams or
 less per container or up to 12 suppositories per pack Hyoscine butylbromide; for oral use in medicines containing not more than 20 milligrams per dose form and in packs containing not more than 10 tablets or capsules for the relief of muscle spasm of the gastrointestinal tract Ibuprofen; for oral use in tablets or capsules containing up to 400 milligrams per dose form and in packs containing not more than 50 dose units and that have received the consent of the Minister or the Director-General to their
 distri- bution as restricted medicines, when sold in the manufacturer’s original pack labelled for use by adults or children over 12 years of age Inositol nicotinate Isoconazole; for vaginal use Ketoprofen; in solid dose form containing 25 milligrams or less per dose form in packs of not more than 30 capsules or tablets 34 35 36 37 38 39 40 41 42 43 44 45 68 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 46 47 Lansoprazole; in divided solid dosage forms for oral use containing 15 milli- grams or less with a maximum daily dose of 15 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over for the relief of heartburn when sold in the manufacturer’s original pack containing not more than 14 dosage units Levonorgestrel; in medicines for use as emergency post-coital contraception when in packs containing not more than 1.5 milligrams except when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health 48 Macrogols; in oral preparations for bowel cleansing prior to diagnostic, medic- al, or surgical procedures 49 Malathion; for external use in medicines containing more than 2% 50 Mannityl hexanitrate 51 Meclozine; in a pack size of up to 10 dosage units for the treatment of anxiety or insomnia 52 Mepyramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety
 or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufactur- er’s original pack containing not more than 10 dosage units 53 Methdilazine; for oral use 54 Metoclopramide; when compounded with paracetamol in packs of not more than 10 tablets or capsules for the treatment of nausea associated with migraine 55 Miconazole; for the treatment of oral candidiasis; for vaginal use 56 57 58 59 60 61 Nicotinic acid except nicotinamide; in medicines containing 250 milligrams or less
 but more than 100 milligrams per dose form Nicotinyl alcohol; in medicines containing more than 100 milligrams per dose form Nystatin; for the treatment of oral candidiasis; for vaginal use Omeprazole; in tablets or capsules containing 20 milligrams or less when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine Orlistat; in medicines for weight control containing 120 milligrams or less per dose form Oseltamivir; in solid dosage forms for oral use containing 75 milligrams in a pack size of up to 10 dosage units for the treatment or prophylaxis of influenza in adults and children aged 13 years and older who have been exposed to the influenza virus 62 Oxiconazole; for vaginal use 69 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 Pantoprazole; in tablets or capsules containing 20 milligrams or less of panto- prazole when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine Pheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufactur- er’s original pack containing not more than 10 dosage units Pneumococcal vaccine; in oral vaccines for the prophylaxis of bacterial com- plications of colds Podophyllotoxin; for external use for the treatment of warts other than anogeni- tal warts
 in medicines containing 1% or less and more than 0.5%; except in medicines containing 1 milligram or less of podophyllin per litre or per kilo- gram Podophyllum emodi; for external use for the treatment of warts other than ano- genital warts in medicines containing 20% or less and more than 10% of podo- phyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram Podophyllum peltatum; for external use for the treatment of warts other than anogenital warts in
 medicines containing 20% or less and more than 10% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram Prochlorperazine; in packs containing not more than 10 tablets or capsules for the treatment of nausea associated with migraine Promethazine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufactur- er’s original pack containing not more than 10 dosage units Rizatriptan; for oral use in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms, when in wafers containing 5 milligrams or less per wafer and when sold in a pack containing not more than 2 wafers approved by the Minister or the Director-General for distribution as a restricted medicine Salicylic acid; except in medicines for dermal use containing 40% or less Santonin Sodium phosphate; in oral preparations for bowel cleansing prior to diagnostic, medical, or surgical procedures Sodium picosulphate; in oral preparations for bowel cleansing prior to diagnos- tic, medical, or surgical procedures Staphyloccocus aureus vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds 63 64 65 66 67 68 69 70 71 72 73 74 75 76 70 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 77
 78 79 80 81 82 83 84 85 86 Stramonium; for oral use in liquid form; in solid dose form in medicines con- taining more than 0.3 milligrams per dose or more than 1.2 milligrams per rec- ommended daily dose Streptococcus beta-haemolyticus vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds Sulfacetamide; for ophthalmic use in medicines containing 10% or less Sumatriptan; for oral use in medicines for the acute relief of migraine attacks with or without aura in patients
 who have a stable, well-established pattern of symptoms when in tablets containing 50 milligrams or less per tablet and when sold in a pack containing not more than 2 tablets that has received the consent of the Minister or the Director-General to its sale as a restricted medicine Theophylline; in liquid form for oral use in medicines containing 2% or less Tioconazole; for vaginal use Triamcinolone; for buccal use in medicines containing 0.1% or less of triamci- nolone acetonide and in pack sizes of 5 grams or less Trimeprazine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufactur- er’s original pack containing not more than 10 dosage units Triprolidine; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule Zolmitriptan; in a pre-filled nasal spray device containing not more than 5 mil- ligrams of zolmitriptan, for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms and when sold in a pack of not more than 2 devices approved by the Minister or the Director-General for distribution as a restricted medicine Part 3 Pharmacy-only medicines 8-hydroxyquinoline and its non-halogenated derivatives; in medicines contain- ing more than 1% of such substances Acetic acid
 and preparations containing more than 80% of acetic acid (CH3COOH); excluding its salts and derivatives Acetylcysteine; for oral use in medicines containing more than 1 gram per rec- ommended daily dose Aciclovir; for external use for the treatment of herpes labialis except in medi- cines containing 5% or less and in tubes containing 10 grams or less Aconitum spp; for oral use in packs containing 0.2 milligrams or less and more than 0.02 milligrams of total alkaloids; for dermal use in concentrations of
 71 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 0.02% or less and in packs containing 0.2 milligrams or less and more than 0.02 milligrams of total alkaloids Aloes; for internal use; except when obtained solely from the mucilaginous gel of the leaf Aloin Aloxiprin Amethocaine; for external use in medicines containing 10% or less and more than 2% Amorolfine; in preparations for topical use except in preparations for the treat- ment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board Antazoline; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board Atropa belladonna; for external use in medicines containing 0.03% or less of the alkaloids of belladonna; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milli- grams per recommended daily dose of the alkaloids of belladonna or in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of the alkaloids of bel- ladonna Atropine; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recom- mended daily dose or in solid dose form in medicines containing 0.3 milli- grams or less per dose form and not more than 1.2 milligrams per recommen- ded daily
 dose; in medicines containing atropine sulphate for the treatment of organophosphorus poisoning either in packs of not more than 20 dose units containing 0.6 milligrams or less per dose unit or in injections in packs of not more than 5 vials containing 0.6 milligrams per millilitre; except when sold as an antidote in a device designed for self-injection from outlets licensed to sell organophosphorus poisons; except in medicines containing 300 micrograms or less per litre or per kilogram Azelaic acid; for
 dermal use Azelastine; for nasal use; in topical eye preparations containing 0.05% or less Beclomethasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 50 micrograms per actuation when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril) in a pack containing 200 actuations or less Benzocaine; in preparations for topical use, other than eye drops, containing 10% or less of total anaesthetic substances except in dermal preparations con- taining 2% or less of total anaesthetic substances; in divided preparations con- 72 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 26 27 28 29 30 31 32 33 taining 200 milligrams or less of total anaesthetic substances per dosage unit except in lozenges containing 30 milligrams or less of total anaesthetic sub- stances per dosage unit Benzoyl peroxide; for external use in medicines containing more than 5% and not more than 10% Benzydamine; for external use except for dermal use Bephenium Bifonazole; for dermal use except in medicines for tinea pedis only or in sham- poos containing 1% or less Bisacodyl Bromhexine Brompheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other thera- peutically active ingredients either when in the bedtime dose of a
 day/night pack containing brompheniramine or when at least 1 of the other active ingre- dients is a sympathomimetic decongestant Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 50 mi- crograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril) in a pack containing 200 actuations or less Carbetapentane; in medicines containing more than
 0.5% Carbocisteine Cetirizine; for oral use except in divided solid dosage forms for oral use con- taining 10 milligrams or less of cetirizine hydrochloride per dose form for the treatment of seasonal allergic rhinitis when sold in the manufacturer’s original pack containing not more than 5 days’ supply Chlophedianol Chlorbutol; in medicines containing 5% or less and more than 0.5% Chloroform; in medicines other than for anaesthesia containing more than 0.5% Chlorpheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other thera- peutically active ingredients either when in the bedtime dose of a day/night pack containing chlorpheniramine or when at least 1 of the other active ingredi- ents is a sympathomimetic decongestant Ciclopirox; for external use in medicines containing 2% or less except when for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board; in preparations for application to the nails containing 8% or less 73 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 34 35 36 37 38 39 40 41 42 43 44 45 46 Cinchocaine; for external use in medicines containing 0.5% or less Cinnamedrine Clotrimazole; for external use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board Cocaine; in medicines for oral use, containing not more than 0.1% of cocaine,
 when combined with 1 or more active ingredients in such a way that the sub- stance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, and when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine Codeine; in medicines for oral use, containing not more than 15 milligrams of codeine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of codeine, when
 combined with 1 or more ac- tive ingredients in such a way that the substance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, for the treatment of the symptoms of cough and cold and when sold in a pack of not more than 6 days’ supply, approved by the Minister or the Director-General for distribution as a pharmacy-only medicine Colocynth Creosote; in medicines containing more than 10% Cresols; in medicines containing more than 3% Datura spp; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per rec- ommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids Delphinium staphisagria; in medicines containing more than 0.2% Desloratadine; for oral use Dexchlorpheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other thera- peutically active ingredients either when in the bedtime dose of a day/night pack containing dexchlorpheniramine or when at least 1 of the other active in- gredients is a sympathomimetic decongestant Dextromethorphan; in liquid form containing more than 0.25% or in solid dose form containing more than 15 milligrams per dose form when in packs contain- ing not more than 600
 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of the symptoms of cough and cold in children aged 6–12 years 47 Dibrompropamidine; for ophthalmic use except when sold in practice by an op- tometrist registered with the Optometrists and Dispensing Opticians Board 74 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 48 49 50 51 52 53 54 55 56 57 Diclofenac; in solid dose form in medicines containing 12.5 milligrams or less per dose form
 in packs containing not more than 30 tablets or capsules and with a recommended daily dose of not more than 75 milligrams Diphenoxylate; in liquid form containing in each millilitre not more than 0.5 milligrams of diphenoxylate calculated as base and not less than 5 micrograms of atropine sulphate; in solid dose form containing not more than 2.5 milli- grams of diphenoxylate calculated as base and not less than 5 micrograms of atropine sulphate Dimenhydrinate; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults or chil- dren over 2 years of age except when sold at a transport terminal or aboard a ship or aircraft Diphenhydramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other thera- peutically active ingredients either when in the bedtime dose of a day/night pack containing diphenhydramine or when at least 1 of the other active ingredi- ents is a sympathomimetic decongestant; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults and children over 2 years of age except when sold at a trans- port terminal or aboard a ship or aircraft Doxylamine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the
 bedtime dose of a day/night pack contain- ing doxylamine or when at least 1 of the other active ingredients is a sympatho- mimetic decongestant Duboisia leichhardtii; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milli- grams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total
 solanaceous al- kaloids Duboisia myoporides; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milli- grams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous al- kaloids Econazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board Etafedrine Ether; in medicines containing more than 10% 75 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 Etofenamate; for external use Famotidine; for the symptomatic relief of heartburn, dyspepsia, and hyperacidi- ty or to be used on the recommendation of a registered medical practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’ supply Felbinac; for external use Fexofenadine; for oral use except for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 10 dosage units or less and not more than 5 days’ supply Fluorides; for internal use in medicines containing 0.5
 milligrams or less per dose unit; except in parenteral nutrition replacement preparations; for external use in liquid form in medicines containing 1 gram or less per litre or per kilo- gram and when sold in packs approved by the Minister or the Director-General for distribution as pharmacy-only medicines except in medicines containing 220 milligrams or less per litre or per kilogram and in packs containing not more than 120 milligrams of total fluoride; except when supplied to any dental professional registered
 with the Dental Council; except in medicines containing 15 milligrams or less per litre or per kilogram Flurbiprofen; in locally acting oromucosal preparations containing 10 milli- grams or less per dosage unit Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose) in a pack containing 200 actuations or less Folic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose Folinic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose Formaldehyde; in medicines containing more than 5% Gelsemium sempervirens; except in medicines containing 1 milligram or less per litre or per kilogram Glutaraldehyde Hexachlorophane; in medicines containing 3% or less but more than 0.75% Hydrocortisone and hydrocortisone acetate but no other esters of hydrocorti- sone; for dermal use in medicines containing 0.5% or less by weight of hydro- cortisone base with no other active ingredient except an antifungal and in a quantity of 30 grams or less or 30 millilitres or less per container; in rectal medicines containing 0.5% or less by weight of hydrocortisone base and in 58 59 60 61 62 63 64 65 66 67 68 69 70 71 76 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule combination with a local anaesthetic
 and in a quantity of 35 grams or less per container or 12 suppositories or fewer per pack Hydrocyanic acid; for oral use in packs containing 5 milligrams or less and more than 0.5 milligrams; except in medicines containing 1 microgram or less per litre or per kilogram Hydroquinone; for external use in medicines containing 2% or less except in hair preparations containing 1% or less Hyoscine; for transdermal use in medicines containing 2 milligrams or less of total solanaceous alkaloids per dose unit; for
 oral use in liquid form in medi- cines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous al- kaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids Hyoscyamine; for external use in medicines containing 0.03% or less of total solanaceous alkaloids; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milli- grams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous al- kaloids Hyoscyamus niger; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids or in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose except in packs contain- ing 30 micrograms or less of total solanaceous alkaloids Ibuprofen; for oral use in liquid form with a recommended daily dose of not more than 1.2 grams for the relief of pain and reduction of fever or inflamma- tion when sold in the manufacturer’s original pack containing
 not more than 8 grams; for oral use in solid dose form containing not more than 200 milligrams per dose form and with a recommended daily dose of not more than 1.2 grams when sold in the manufacturer’s original pack containing not more than 100 dose units; except in divided solid dosage forms for oral use containing 200 milligrams or less per dose form with a recommended daily dose of not more than 1.2 grams and when sold in the manufacturer’s original pack containing not more than 25 dose units
 Indanazoline Indomethacin; for external use in medicines containing 1% or less; except in medicines containing 1 milligram or less per litre or per kilogram 72 73 74 75 76 77 78 79 77 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 Iodine; for external use in medicines containing more than 2.5%; for internal use in medicines containing 300 micrograms or more per recommended daily dose Ipecacuanha; in medicines containing 0.2% or less of emetine and 40 micro- grams or more of ipecacuanha alkaloids per recommended dose for the treat- ment of the symptoms of cough and cold in children aged 6–12 years Ipomoea spp; except ipomoea batatas Ipratropium; for nasal use Iron; for oral use either in medicines containing more than 24 milligrams per recommended daily dose or in medicines containing more than 5 milligrams per dose unit and more than 750 milligrams of iron per pack; except in paren- teral nutrition replacement preparations Isoconazole; for dermal use except when sold in practice by a podiatrist regis- tered with the Podiatrists Board Isopropamide; for dermal use in preparations containing 2% or less Jalap resin Ketoconazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board; except in medicines for treatment of the scalp containing 1% or less Ketotifen; for ophthalmic use in medicines containing 0.025% or less except when sold in practice by an optometrist registered
 with the Optometrists and Dispensing Opticians Board Leucovorin; in medicines containing more than 500 micrograms per recom- mended daily dose Levocabastine; for nasal use; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board Levocetirizine; for oral use Lignocaine; for urethral use; for external use in medicines containing 10% or less and more than 2% Lindane; for external use in medicines containing 2% or less Lithium; for dermal
 use in medicines containing 1% or less but more than 0.01%; except when present as an excipient in dermal medicines containing 0.25% or less Lobelia inflata; except in medicines for smoking or burning Lobeline; except when in medicines for smoking or burning Lodoxamide; for ophthalmic use except when sold in practice by an optomet- rist registered with the Optometrists and Dispensing Opticians Board 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 78 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 99 Loperamide; in packs containing not more than 20 tablets or capsules; except in divided solid dosage forms for oral use containing 2 milligrams or less of loperamide per dosage form when sold in a pack containing not more than 8 dosage forms approved by the Minister or the Director-General for distribution as a general sales medicine for the symptomatic treatment of acute non-specific diarrhoea 100 Loratadine; for oral use except in divided solid dosage forms for oral use con- taining 10 milligrams or less per dose form for the treatment of seasonal aller- gic rhinitis when sold in the manufacturer’s original pack containing not more than 5 days’ supply 101 Mebendazole 102 Meclozine; in a sealed container of not more than 12 tablets or capsules for the prevention or treatment of travel sickness except when sold at a transport ter- minal or aboard a ship or aircraft 103 Mefenamic acid; in solid dose form in packs containing not more than 30 tab- lets or
 capsules for the treatment of dysmenorrhoea 104 Mepyramine; for dermal use 105 Mercuric oxide; for ophthalmic use 106 Mercurochrome; in preparations for external use containing 2% or less 107 Mercury; for external use in medicines containing 0.5% or less 108 Methoxamine; for external use in medicines containing more than 1% 109 Methoxyphenamine 110 Methylephedrine 111 Miconazole; for external use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the
 Podiatrists Board 112 Minoxidil; for dermal use in medicines containing 5% or less 113 Mometasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 50 mi- crograms per actuation when the maximum recommended daily dose is no greater than 200 micrograms (as a single dose) in a pack containing 200 actua- tions or less 114 Morphine; in medicines for oral use containing not more than 0.2% of mor- phine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine 115 Naphazoline; except for ophthalmic use when sold in practice by an optomet- rist registered with the Optometrists and Dispensing Opticians Board 116 Naproxen; in solid dose form containing 250 milligrams or less per dose form in packs of not more than 30 tablets or capsules 79 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 117 Niclosamide 118 Nicotine; for inhalation except when sold from a smoking cessation clinic run under the auspices of a registered medical practitioner, nurse, pharmacist, or psychologist 119 Nizatidine; in medicines for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical
 practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’ supply 120 Noscapine 121 Nystatin; for dermal use except when sold in practice by a podiatrist registered with the Podiatrists Board 122 Omeprazole; in divided solid dosage forms for oral use containing 20 milli- grams or less with a maximum daily dose of 20 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over when sold in the manufacturer’s original pack
 containing not more than 28 dosage units 123 Opium; in medicines for oral use containing not more than 0.2% of morphine, when combined with 1 or more active ingredients in such a way that the sub- stance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine 124 Oxetacaine; for internal use 125 Oxiconazole; for dermal use except in medicines for tinea pedis only 126 Oxymetazoline; except for nasal use when sold at an airport; except for oph- thalmic use when sold in practice by an optometrist registered with the Optom- etrists and Dispensing Opticians Board; except for nasal use in medicines con- taining 0.05% or less when sold in the manufacturer’s original pack with a pack size of 20 millilitres or less 127 Pantoprazole; in divided solid dosage forms for oral use containing 20 milli- grams or less with a maximum daily dose of 20 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over when sold in the manufacturer’s original pack containing not more than 28 dosage units 128 Papaverine; except for injection 129 Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams; in slow- release forms containing 665 milligrams or less and more than 500 milligrams; in
 powder form containing not more than 1 gram per sachet and more than 10 grams per pack 130 Paraformaldehyde; in medicines containing more than 5% 80 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 131 Penciclovir; for external use for the treatment of herpes labialis 132 Phedrazine 133 Phenazone; for external use 134 Pheniramine; for ophthalmic use except when sold in practice by an optomet- rist registered with the Optometrists and Dispensing Opticians Board; for oral use in medicines for
 adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing pheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongest- ant 135 Phenol; in medicines other than for injection containing more than 3% 136 Phenylephrine; for nasal use in medicines containing more than 1%; for oph- thalmic use in medicines containing 5% or less and more than 1%; for oral use in medicines containing more than 50 milligrams per recommended daily dose or in packs containing more than 250 milligrams of phenylephrine per pack; in medicines for the treatment of the symptoms of cough and cold in children aged 6–12 years 137 Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for dis- tribution as a pharmacy-only medicine 138 Piperazine 139 Podophyllotoxin; for external use for the treatment of warts other than anogeni- tal warts in medicines containing 0.5% or less; except in medicines containing 1 milligram or less of
 podophyllin per litre or per kilogram 140 Podophyllum emodi; for external use for the treatment of warts other than ano- genital warts in medicines containing 10% or less of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilo- gram 141 Podophyllum peltatum; for external use for the treatment of warts other than anogenital warts in medicines containing 10% or less of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilo-
 gram 142 Potassium; for internal use: in slow-release or enteric coated forms; in medi- cines containing more than 100 milligrams per recommended dose except in medicines for oral rehydration therapy, parenteral nutrition replacement, or di- alysis; except in glucosamine sulphate complexed products containing 600 mil- ligrams or less of potassium chloride per recommended dose 81 Schedule Medicines Amendment Regulations (No 2) 2015 2015/180 143 Potassium chlorate; except in medicines containing 10% or less 144 Prilocaine; for dermal use in medicines containing 10% or less of local anaes- thetic substances 145 Procyclidine; for dermal use in medicines containing 5% or less 146 Promethazine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack contain- ing promethazine or when at least 1 of the other active ingredients is a sympa- thomimetic decongestant; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults and children over 2 years of age except when sold at a transport terminal or aboard a ship or aircraft 147 Propamidine; for ophthalmic use except when sold in practice by an optomet- rist registered with the Optometrists and Dispensing Opticians Board 148 Pyrantel 149 Pyrethrins; in medicines containing more than 10% 150
 Pyrithione zinc; except in medicines for treatment of the scalp containing 2% or less 151 Ranitidine; in medicines for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’ supply; except in medicines containing 150 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than 7 days’ supply 152 Salicylamide
 153 Selenium; for oral use in medicines containing 300 micrograms or less and more than 150 micrograms per recommended daily dose; for external use ex- cept in medicines containing 3.5% or less of selenium sulphide 154 Sennosides 155 Silver; except in oral solutions containing 0.3% or less or other medicines con- taining 1% or less 156 Silver sulfadiazine; for external use in pack sizes of 50 grams or less 157 Sodium cromoglycate; for nasal use; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Op- ticians Board 158 Sodium nitrite; except for use as an excipient 159 Sodium picosulphate; in oral laxative preparations 160 Squill; in medicines containing more than 1% 82 2015/180 Medicines Amendment Regulations (No 2) 2015 Schedule 161 Stramonium; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per rec- ommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids 162 Sulconazole; for dermal use 163 Sulfadiazine, silver; for external use in pack sizes of 50 grams or less 164 Terbinafine; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board 165 Tetrachloroethylene 166
 Tetrahydrozoline; except for ophthalmic use when sold in practice by an op- tometrist registered with the Optometrists and Dispensing Opticians Board 167 Thiabendazole 168 Tioconazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board 169 Tramazoline 170 Triamcinolone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age and when in aqueous nasal sprays delivering up to 55 micrograms per
 actuation when the maximum recommended daily dose is no greater than 220 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine 171 Trimeprazine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack contain- ing trimeprazine or when at least 1 of the other therapeutically active ingredi- ents is a sympathomimetic decongestant 172 Triprolidine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack contain- ing triprolidine or when at least 1 of the other active ingredients is a sympatho- mimetic decongestant 173 Tuaminoheptane 174 Tymazoline 175 Xylenols; in medicines containing more than 3% 176 Xylometazoline; except for nasal use when sold at an airport; except for oph- thalmic use when sold in practice by an optometrist registered with the Optom- etrists and Dispensing Opticians Board 177 Zinc chloride; for dermal use in medicines containing more than 5% 83 Explanatory note Medicines Amendment Regulations (No 2) 2015 2015/180 Michael Webster, Clerk of the Executive Council.
Explanatory note This note is not part of the regulations, but is intended to indicate their general effect.

These regulations, which come into force on 6 August 2015, replace Schedule 1 of the Medicines Regulations 1984 (the principal regulations).

New Schedule 1 sets out an updated list of specified medicines and classes of medicines that are declared to be prescription medicines, restricted medicines, or pharmacy-only medicines under the Medicines Act 1981 (the Act).
The updated list includes medicines that the Minister of Health has previously classi- fied as prescription medicines, etc, by Gazette notice made under section 106 of the Act (see Classification of Medicines (Gazette 2015-go984) and Classification of Medicines (Gazette 2014-go7770)).
Gazette notices made under section 106 override any inconsistent classification of medicines in the principal regulations, but they do not amend the principal regulations and they cease to have effect after a period of 6 months (if not revoked sooner).

Issued under the authority of the Legislation Act 2012.

Date of notification in Gazette: 30 July 2015.

These regulations are administered by the Ministry of Health.
Wellington, New Zealand: Published under the authority of the New Zealand Government—2015 84